

Drug resistance interpretation: PR		HIVDB 9.5.1 (2023-11-05)
PI Major Mutations:	None	
PI Accessory Mutations:	None	
PR Other Mutations:	I13V 10% cons:12,475 • I15V 14% cons:12,492 • G16E 10% cons:12,505 • K20R 10% cons:12,517 • E33D 14% cons:12,629 • M36I 100% cons:12,631 • R41K 10% cons:12,651 • K45R 10% cons:12,672 • R57K 10% cons:14,521 • L63S 10% cons:12,545 • H69K 12% cons:12,445 • K70R 11% cons:12,445 • L89M 100% cons:12,525	
Protease Inhibitors		
atazanavir/r (ATV/r)	Susceptible	
darunavir/r (DRV/r)	Susceptible	
fosamprenavir/r (FPV/r)	Susceptible	
indinavir/r (IDV/r)	Susceptible	
lopinavir/r (LPV/r)	Susceptible	
nelfinavir (NFV)	Susceptible	
saquinavir/r (SQV/r)	Susceptible	
tipranavir/r (TPV/r)	Susceptible	
PR comments		
Other		
<ul style="list-style-type: none">K20R is a highly polymorphic PI-selected accessory mutation that increases replication fitness in viruses with PI-resistance mutations.		

Mutation scoring: PR	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for PI.	

Drug resistance interpretation: RT

HIVDB 9.5.1 (2023-11-05)

NRTI Mutations:

None

NNRTI Mutations:

None

RT Other Mutations:

V35T ^{100%}_{cons:1,590} • T39A ^{10%}_{cons:424} • S48T ^{11%}_{cons:152} • V60I ^{14%}_{cons:65} • K122E ^{100%}_{cons:159} • D123S ^{14%}_{cons:168} • I135T ^{10%}_{cons:171} • I142V ^{10%}_{cons:177} • K166R ^{10%}_{cons:481} • K173AT ^{1,100%}_{cons:177} T:100% • V179I ^{10%}_{cons:179} • Q197K ^{100%}_{cons:164} • T200A ^{100%}_{cons:161} • V245Q ^{10%}_{cons:164} • E514D ^{10%}_{cons:1,862} • L517I ^{100%}_{cons:2,034} • S519N ^{10%}_{cons:2,047} • Q520QL ^{1,100%}_{cons:2,035} Q:100% Q:40% • Q524QK ^{1,100%}_{cons:2,410} K:100% • K527G ^{10%}_{cons:2,705} • E529D ^{100%}_{cons:5,122} • A534S ^{10%}_{cons:4,032} • A554S ^{10%}_{cons:5,177}

Nucleoside Reverse Transcriptase Inhibitors

abacavir (ABC)

Susceptible

zidovudine (AZT)

Susceptible

stavudine (D4T)

Susceptible

didanosine (DDI)

Susceptible

emtricitabine (FTC)

Susceptible

lamivudine (3TC)

Susceptible

tenofovir (TDF)

Susceptible

Non-nucleoside Reverse Transcriptase Inhibitors

doravirine (DOR)

Susceptible

efavirenz (EFV)

Susceptible

etravirine (ETR)

Susceptible

nevirapine (NVP)

Susceptible

rilpivirine (RPV)

Susceptible

RT comments

Other

V179I

 is a polymorphic mutation that is frequently selected in persons receiving ETR and RPV. However, it has little, if any, direct effect on NNRTI susceptibility.

Mutation scoring: RT	HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for NRTI.	
No drug resistance mutations were found for NNRTI.	

Drug resistance interpretation: IN		HIVDB 9.5.1 (2023-11-05)
INSTI Major Mutations:	None	
INSTI Accessory Mutations:	None	
IN Other Mutations:	K14R ^{10%} _{cons:4,540} • I72V ^{100%} _{cons:12,811} • P90PQ ^{1,100%} _{cons:4,870} P:100% • G106A ^{10%} _{cons:234} • T112V ^{10%} _{cons:234} • I113V ^{10%} _{cons:239} • T124A ^{10%} _{cons:145} • T125A ^{10%} _{cons:145} • G134N ^{10%} _{cons:1,124} • K136Q ^{10%} _{cons:1,124} • V201I ^{10%} _{cons:4,264} • L234I ^{10%} _{cons:1,504} • D256E ^{100%} _{cons:1,917} • V281VM ^{1,100%} _{cons:5,756} V:100%, M:40% • S283G ^{100%} _{cons:5,284} • R284G ^{100%} _{cons:5,284} • D288N ^{100%} _{cons:5,302}	
Integrase Strand Transfer Inhibitors		
bictegravir (BIC)	Susceptible	
cabotegravir (CAB)	Susceptible	
dolutegravir (DTG)	Susceptible	
elvitegravir (EVG)	Susceptible	
raltegravir (RAL)	Susceptible	
Mutation scoring: IN		HIVDB 9.5.1 (2023-11-05)
No drug resistance mutations were found for INSTI.		